Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05139108
Other study ID # QianfoshanH TEE-AKI
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 6, 2021
Est. completion date September 30, 2023

Study information

Verified date November 2021
Source Qianfoshan Hospital
Contact binghua liu, master
Phone 18560293562
Email liubinghua042525@126.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

TEE has a definite effect on the evaluation of cardiac structure and function in perioperative cardiac surgery. However, in CABG, previous studies on TEE mainly focused on whether to change the surgical plan rather than improve the clinical prognosis. There are few related studies on the evaluation of prognosis, and these studies have low efficacy and inconsistent conclusions. Acute kidney injury is the most common complication of CABG surgery and is independently associated with hospitalization and long-term mortality. In CABG patients, acute kidney injury, in addition to operation-related factors, is closely related to renal perfusion. These patients often exist serious coronary multivessel lesions and right heart dysfunction, which can cause the system obstacle of regurgitation of the inferior vena cava and kidney blood stasis, while the inappropriate rehydration fluid overload will affect kidney blood perfusion, which may be one of the reasons for the kidney injury. Therefore, appropriate volume status plays an important role in maintaining right heart function and renal perfusion. What indicators can the investigators use to effectively evaluate the patient's volume status and monitor the patient's right heart function? In recent years, ultrasound has been used as an effective tool to assess patient volume status , right heart function, and to guide patient fluid management. Many studies have confirmed that the respiratory variability of inferior vena cava diameter (ΔIVC) measured by TTE has a good correlation with the volume status of patients on mechanical ventilation, which has a high diagnostic value for predicting the fluid responsiveness and guiding fluid management.However, no study has been reported using TEE measurements of ΔIVC to assess volume status and guide fluid management in patients undergoing cardiac bypass surgery. Previous studies have confirmed that TAPSE measured by TTE is independently associated with AKI in ICU patients and can predict the occurrence of AKI in such patients. However, TAPSE monitored by TEE have not been reported in this regard. Can ΔIVC and TAPSE predict the incidence of AKI and major cardiovascular and cerebrovascular adverse events in CABG patients? Therefore, the investigators designed this observational study to further scientifically confirm the validity and guiding significance of ΔIVC and TAPSE in CABG, so as to protect and improve patients' renal function , reduce postoperative mortality and improve the clinical prognosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients aged =18 years; - Patients undergoing elective isolated coronary artery bypass surgery (with or without bypass); - In line with ethics, the patients volunteered to take the test and signed the informed consent for the clinical study; Exclusion Criteria: - Patients with severe renal insufficiency before surgery; - Preoperative patients with moderate or more than moderate valvular lesions required surgery; - Diabetic patients with a history of serious diabetic complications (diabetic ketoacidosis, hyperosmolar coma, various infections, macrovascular lesions, diabetic nephropathy); - Patients with TEE contraindications

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Shandong Provincial Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University Jinan Shandong

Sponsors (2)

Lead Sponsor Collaborator
Qianfoshan Hospital Zibo Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the incidence of postoperative acute kidney injury acute kidney injury after cardiac surgery Within 7 days after surgery
Secondary the incidence of major postoperative cardiovascular and cerebrovascular adverse events major postoperative cardiovascular and cerebrovascular adverse events after cardiac surgery Within 30 days after surgery
Secondary the incidence of pulmonary complications pulmonary complications included pulmonary infection,pulmonary atelectasis, acute lung injury, respiratory failure after cardiac surgery Within 30 days after surgery
Secondary ICU endotracheal intubation time ICU endotracheal intubation time Within 30 days after surgery
See also
  Status Clinical Trial Phase
Completed NCT04523064 - POST-CABGDM: Empagliflozin in Perioperative CABG Phase 4
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Completed NCT01467232 - IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting Phase 2
Completed NCT04631809 - Computed Tomography Coronary Angiography in Patients With a Previous Coronary Artery Bypass Graft Surgery Trial N/A
Completed NCT00073580 - Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) Phase 3
Terminated NCT03346278 - Text Message Intervention to Improve Cardiac Rehab Participation N/A
Completed NCT00303641 - Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients Phase 1
Completed NCT03823521 - Observational Study to Investigate the Effects of Training on the Administration of Cardioplexol™ Phase 3
Terminated NCT00789399 - A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis N/A
Completed NCT02592824 - Glutamate for Metabolic Intervention in Coronary Surgery II Phase 3
Not yet recruiting NCT05079724 - Acute Kidney Injury After Cardiac Surgery
Withdrawn NCT04379947 - Preoperative Use of Fractional Flow Reserve in CABG Use and Effectiveness of FFR-based CABG in Real-life Practice
Terminated NCT00858936 - Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery Phase 2
Recruiting NCT01386229 - A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery Phase 4
Completed NCT00653042 - Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA Phase 2
Completed NCT00318227 - Randomized Trial of a Liberal Versus a Restrictive Transfusion Strategy in Elderly Cardiac Surgery Patients N/A
Completed NCT00372671 - Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation Phase 3
Completed NCT00209521 - Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery Phase 2
Not yet recruiting NCT05396690 - Safety and Efficacy of Remimazolam in OPCAB Surgery N/A
Recruiting NCT05411445 - Study of Role of Blood Microvescicles and Exosomes in Patients With Graft Occlusion After Aortocoronary Bypass Surgery